BrainStorm to Present at Several Scientific and Investment

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Apr 10, 2013) - BrainStorm Cell Therapeutics ( OTCQB : BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the company will be presenting at several upcoming scientific and investment conferences.

Bizportal Biomed 2013 Conference
On April 10 ^th in Tel Aviv, Alon Natanson, CEO, will make a presentation about the company's recent scientific and business developments to institutional and life science investors at the Bizportal Biomed 2013 Conference.

Israstem
On April 22 ^nd at 10:40 a.m. in Ramat Gan, Israel, Professor Daniel Offen, Chief Scientific Advisor, will present a Keynote Lecture titled "Transplantation of Mesenchymal Stromal Cells Secreting Neurotrophic Factors Shows Safety and Initial Indications of Clinical Benefit in ALS Patients in a Phase I/II Clinical Trial" at IsraStem, the Annual Israeli Meeting of Translational Research on Stem Cells, Cell Therapy and Regenerative Medicine in Industry and Academia.

ALS Canada Research Forum
On May 4 ^th in Toronto, Ontario, Professor Daniel Offen, Chief Scientific Advisor, will deliver a poster presentation about the results from the recently completed Phase I/II clinical trial at the 9 ^th Annual Meeting of the ALS Research Forum of the ALS Society of Canada.

Oppenheimer's 14 ^th Annual Israeli Conference
On May 12 ^th at 13:45 in Tel Aviv, Alon Natanson, CEO, will make a presentation about the company's recent scientific and business developments to Israeli financial institutions at Oppenheimer's 14 ^th Annual Israeli Conference.

ALSTDI Webinar
On May 8 ^th at 10:00 am EST, Dr. Yael Gothelf, VP Scientific & Regulatory Affairs, will discuss the company's clinical trials program for NurOwn™ at a live webinar sponsored by the ALS Therapy Development Institute. To register for this webinar, go to: http://bit.ly/Zmk3ov .

About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com .

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov . These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.